IGC Pharma reported its Q2 2026 financial results, with GAAP EPS missing estimates but revenue beating expectations. The company also announced that its CALMA Alzheimer's trial is nearing enrollment closure.

The CEO and Chief Financial Officer of IGC Pharma have collectively purchased $1.15 million worth of common stock in the company.

Analysts are assessing the investment potential of several healthcare and pharmaceutical companies, including Eli Lilly, IGC Pharma, and 60 Degrees Pharmaceuticals. They are providing insights and recommendations for investors considering these stocks.